ALK

ALK inhibitors cover anaplastic lymphoma kinase and activin receptor-like kinases, two unrelated groups named ALK. Anaplastic lymphoma kinase was identified in 1994 as a tyrosine kinase fused to nucleophosmin (NPM) in a non-Hodgkin lymphoma. In 2007 a fusion with echinoderm microtubule-associated protein-like 4 (EML4) was found in non-small-cell lung cancer. Crizotinib, TAE684, brigatinib and entrectinib inhibit anaplastic lymphoma kinase, and entrectinib also blocks tropomyosin receptor kinases (Trk). Activin receptor-like kinases (ALKs) are type I receptors for transforming growth factor beta (TGF-β) family ligands. A 83-01 inhibits ALK4, ALK5 and ALK7 and blocks Smad signaling by TGF-β. Vactosertib also targets ALK4 and ALK5, while LDN193189 and DMH-1 inhibit the bone morphogenetic protein receptor ALK2.

Items 76-100 of 150

  • CEP-14083
    Cat. No.
    A33804

    CEP-14083

    CEP-14083 is an ATP-competitive inhibitor targeting ALK, with IC50 values of 2 nM in enzymatic assays. This compound also inhibits other kinases, including the insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2), and dual leucine zipper kinase (DLK). CEP-14083 has been shown to suppress CD274 mRNA expression and the function of NPM/ALK in NPM/ALK-positive T cell lymphoma cells. It is a valuable tool for research focused on lymphoma and related signaling pathways.

    25 mg
    $2,035.00
    50 mg
    $2,610.00
    All 3 sizes
  • Crizotinib acetate
    Cat. No.
    A34327

    Crizotinib acetate

    Synonyms: PF-02341066 acetate

    Crizotinib acetate is an orally bioavailable inhibitor targeting ALK, c-Met, and ROS1 through ATP competition. It demonstrates potent inhibition of tyrosine phosphorylation in cell-based assays, with IC50 values of 20 nM for ALK, 8 nM for c-Met, 24 nM for NPM-ALK, and 11 nM for c-Met. The compound has shown significant efficacy in inhibiting tumor growth, making it a valuable tool in cancer research and therapeutic applications targeting these pathways.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • CM-118
    Cat. No.
    A34344

    CM-118

    CM-118 is a selective inhibitor of c-Met and ALK, targeting the HGF-induced c-Met phosphorylation and impairing ALK phosphorylation in key variants including EML4-ALKv1, ALK F1174L, and EML4-ALKv1 L1196M. With IC50 values of 0.92, 1.25, 1.9, and 3.5 μM respectively, CM-118 demonstrates significant anticancer activity against tumors reliant on c-Met or ALK oncogenic pathways. This compound is useful for investigating therapeutic strategies in cancers driven by these targets.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • SMU-B
    Cat. No.
    A34348

    SMU-B

    SMU-B is a potent orally active inhibitor of anaplastic lymphoma kinase (ALK) with an IC50 of less than 0.5 nM, along with c-ros oncogene 1 (ROS1) and c-MET, exhibiting IC50 values of 1.87 nM and 28.9 nM for AXL. This compound demonstrates significant antiproliferative activity against MKN45, H1993, and H441 cell lines, with IC50s of 0.02 μM, 1.58 μM, and 2.82 μM, respectively. Additionally, SMU-B has shown promising antitumor efficacy in various mouse models, highlighting its potential for cancer research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Crizotinib-d8
    Cat. No.
    A34379

    Crizotinib-d8

    Synonyms: PF-02341066-d8

    Crizotinib-d8 is a deuterated analog of Crizotinib, functioning as an ATP-competitive inhibitor of ALK and c-Met. This compound exhibits potent biological activity, with IC50 values of 20 nM and 8 nM, respectively, and effectively inhibits tyrosine phosphorylation of NPM-ALK and c-Met in cellular assays. Additionally, Crizotinib-d8 serves as an inhibitor of ROS1. This stable isotope is primarily utilized in pharmacokinetic studies and metabolic research involving Crizotinib to enhance understanding of its therapeutic mechanisms.

    Out of stock

    All 3 sizes
  • SIAIS001
    Cat. No.
    A34501

    SIAIS001

    SIAIS001 is a potent PROTAC degrader targeting anaplastic lymphoma kinase (ALK) with a DC50 of 3.9 nM. This compound induces G1/S phase cell cycle arrest and effectively inhibits the proliferation of SR cells with an IC50 of 0.9 nM. SIAIS001 is suitable for research in non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs).

    Out of stock

    All 3 sizes
  • MS99-β-Gal
    Cat. No.
    A34502

    MS99-β-Gal

    Synonyms: Gal-MS99

    MS99-β-Gal is a galactose-modified PROTAC degrader targeting the NPM-ALK fusion protein. This compound is selectively hydrolyzed by SA-β-gal and esterase in senescent cancer cells, allowing the release of MS99, which effectively degrades the NPM-ALK protein. MS99-β-Gal demonstrates an IC50 of 454.8 nM in aging Karpas 299 cells, showing improved potency compared to normal Karpas 299 cells with an IC50 of 2.162 μM. This reagent is valuable for cancer research, particularly in studies focused on targeted protein degradation.

    Out of stock

    All 3 sizes
  • ALKBH5-IN-3
    Cat. No.
    A34503

    ALKBH5-IN-3

    ALKBH5-IN-3 is a selective inhibitor of the ALKBH5 enzyme, exhibiting an IC50 of 0.021 μM. This compound effectively stabilizes ALKBH5 in HepG2 cells, resulting in an elevated level of m6A in intact cells. ALKBH5-IN-3 serves as a valuable chemical probe for investigating the biological functions of ALKBH5, with significant applications in cancer research.

    5 mg
    $35.00
    10 mg
    $55.00
    All 5 sizes
  • CPD-1224
    Cat. No.
    A34504

    CPD-1224

    CPD-1224 is a potent ALK inhibitor that specifically targets the EML4-ALK oncogenic fusion protein. This compound promotes the degradation of both ALK and its mutant forms, including L1196M and G1202R. CPD-1224 demonstrates significant potential in slowing tumor growth, making it a valuable reagent for cancer research and therapeutic development focused on ALK-driven malignancies.

    1 mg
    $180.00
    5 mg
    $460.00
    All 6 sizes
  • Zotizalkib
    Cat. No.
    A34505

    Zotizalkib

    Synonyms: TPX-0131

    Zotizalkib is a potent and selective inhibitor of anaplastic lymphoma kinase (ALK) with a low IC50 of 1.4 nM for wild-type ALK and 0.3 nM for key ALK-resistant mutations such as G1202R and L1196M. This CNS-penetrant compound demonstrates significant antitumor activity, making it valuable for research in cancer biology and treatment strategies for ALK-driven tumors. Its oral bioavailability and ability to target resistant ALK mutations further enhance its potential in therapeutic applications.

    1 mg
    $100.00
    5 mg
    $245.00
    All 6 sizes
  • M4K2234
    Cat. No.
    A34506

    M4K2234

    M4K2234 is a potent and selective inhibitor of ALK1 and ALK2, with IC50 values of 7 nM and 14 nM, respectively. This compound effectively disrupts BMP signaling by inhibiting the phosphorylation of SMAD1/5/8, thereby reducing BMP7-stimulated reporter activity (IC50 = 16 nM). M4K2234 is suitable for studying ALK1/2-mediated biological pathways and investigating diseases such as diffuse midline glioma (DMG) and fibrodysplasia ossificans progressiva (FOP).

    1 mg
    $40.00
    5 mg
    $100.00
    All 6 sizes
  • Tosposertib
    Cat. No.
    A34507

    Tosposertib

    Synonyms: TU2218 free base

    Tosposertib is a dual inhibitor targeting ALK5 and VEGFR2, with IC50 values of 1.2 nM and 4.9 nM, respectively. This compound effectively restores the functionality of cytotoxic T lymphocytes (CTLs) and natural killer cells that are suppressed by TGFβ, while concurrently inhibiting the activity and viability of regulatory T cells. Tosposertib is valuable for research applications related to melanoma and colon cancer.

    5 mg
    $785.00
    10 mg
    $1,205.00
    All 4 sizes
  • CEP-28122 mesylate salt
    Cat. No.
    A34508

    CEP-28122 mesylate salt

    CEP-28122 mesylate salt is a potent and selective inhibitor of Anaplastic Lymphoma Kinase (ALK), exhibiting an IC50 value of 1.9 nM. This diaminopyrimidine derivative demonstrates significant antitumor activity in preclinical models of ALK-positive human cancers. Its favorable pharmacodynamic and pharmacokinetic profiles support its use in research related to ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma.

    5 mg
    $150.00
    10 mg
    $240.00
    All 4 sizes
  • Entrectinib-d8
    Cat. No.
    A34509

    Entrectinib-d8

    Synonyms: NMS-E628-d8; RXDX-101-d8

    Entrectinib-d8 is a deuterated derivative of Entrectinib, targeting TrkA/B/C, ROS1, and ALK receptors. This compound exhibits potent inhibitory effects with IC50 values of 1 nM for TrkA, 3 nM for TrkB, 5 nM for TrkC, and 12 nM for ROS1 and ALK. Entrectinib-d8 is effective in inducing apoptosis and cell cycle arrest in various cancer cell lines, demonstrating significant anti-tumor activity. Additionally, it has been shown to alleviate bleomycin-induced pulmonary fibrosis in murine models, making it a valuable tool for research in cancer and fibrosis therapies.

    1 mg
    $190.00
    5 mg
    $490.00
    All 3 sizes
  • Ficonalkib
    Cat. No.
    A34510

    Ficonalkib

    Ficonalkib is a potent anaplastic lymphoma kinase (ALK) inhibitor that targets the tyrosine kinase receptor. It exhibits significant antineoplastic activity and is utilized in research to explore therapeutic strategies for ALK-driven malignancies. Its mechanism of action provides valuable insights into cancer biology and potential treatment pathways.

    5 mg
    $175.00
    10 mg
    $310.00
    All 5 sizes
  • ALK-IN-28
    Cat. No.
    A34513

    ALK-IN-28

    ALK-IN-28 is a selective inhibitor of anaplastic lymphoma kinase (ALK), a critical target in various cancers, including non-small cell lung cancer and neuroblastoma. This compound effectively blocks ALK activity, demonstrating significant anti-proliferative effects in ALK-driven tumor models. ALK-IN-28 is suitable for research applications focused on elucidating ALK signaling pathways and exploring potential therapeutic strategies for ALK-positive malignancies.

    1 mg
    $615.00
    5 mg
    $1,010.00
    All 6 sizes
  • Ena15
    Cat. No.
    A34514

    Ena15

    Ena15 is an inhibitor of the ALKBH5 enzyme, which plays a critical role in m6A RNA methylation. This compound enhances the demethylase activity of FTO, leading to increased levels of m6A-modified RNA and stabilization of FOXM1 mRNA. Ena15 demonstrates potent antitumor activity by suppressing the growth of glioblastoma multiforme, making it a valuable tool for research in cancer biology and therapeutic development.

    5 mg
    $120.00
    10 mg
    $195.00
    All 2 sizes
  • ALK kinase inhibitor-1
    Cat. No.
    A34515

    ALK kinase inhibitor-1

    ALK Kinase Inhibitor-1 is a selective anaplastic lymphoma kinase (ALK) inhibitor, identified as compound I-202 from patent US20130261106A1. This compound exhibits potent inhibitory activity against ALK, a crucial target in various cancers, particularly those driven by ALK mutations such as non-small cell lung cancer. It is suitable for research applications aimed at studying ALK-related signaling pathways and evaluating potential therapeutic strategies in oncological contexts.

    5 mg
    $35.00
    10 mg
    $50.00
    All 6 sizes
  • EML4-ALK kinase inhibitor 1
    Cat. No.
    A34517

    EML4-ALK kinase inhibitor 1

    EML4-ALK kinase inhibitor 1 is a potent inhibitor targeting the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), demonstrating an IC50 value of 1 nM. This compound effectively disrupts EML4-ALK signaling pathways, which are implicated in certain types of cancer, particularly non-small cell lung cancer. It serves as a valuable tool for research focused on understanding EML4-ALK-mediated oncogenic processes and exploring therapeutic strategies for EML4-ALK-positive malignancies.

    1 mg
    $70.00
    5 mg
    $185.00
    All 7 sizes
  • ALKBH5-IN-2
    Cat. No.
    A34518

    ALKBH5-IN-2

    ALKBH5-IN-2 is a selective inhibitor of the ALKBH5 enzyme, demonstrating a potent inhibitory effect with an IC50 value of 0.79 µM. This compound has been shown to significantly reduce cell viability, making it a valuable tool for studying the role of ALKBH5 in various biological processes. Applications include investigations into cellular responses to RNA demethylation and exploring its implications in cancer research and epigenetic regulation.

    5 mg
    $125.00
    10 mg
    $210.00
    All 5 sizes
  • TL13-22
    Cat. No.
    A34519

    TL13-22

    TL13-22 is a potent anaplastic lymphoma kinase (ALK) inhibitor with an IC50 of 0.54 nM. As a negative control for TL13-12, it serves as a valuable tool in research involving ALK pathways without inducing degradation of the ALK protein in cells. This compound can be utilized in studies focused on ALK-related cancers and signaling mechanisms.

    1 mg
    $90.00
    5 mg
    $230.00
    All 5 sizes
  • AP-1
    Cat. No.
    A34520

    AP-1

    AP-1 is a PROTAC designed to target anaplastic lymphoma kinase (ALK) for selective degradation. This compound comprises the target protein ligand CS-1243648, the E3 ligase ligand Pomalidomide, and a linker derived from 2-(Tert-Butoxy)-2-oxoacetic acid. AP-1 is valuable for research applications focused on studying ALK-related signaling pathways and the therapeutic potential of targeted protein degradation in cancer treatment.

    1 mg
    $145.00
    5 mg
    $445.00
    All 3 sizes
  • ALK-IN-5
    Cat. No.
    A34522

    ALK-IN-5

    ALK-IN-5 is a highly potent and selective inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an IC50 value of 2.9 nM. This compound effectively crosses the blood-brain barrier, making it suitable for research applications related to ALK-driven malignancies, particularly in neurological contexts. ALK-IN-5 serves as a valuable tool for investigating ALK signaling pathways and developing targeted therapies in cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • CJ-2360
    Cat. No.
    A34523

    CJ-2360

    CJ-2360 is a highly selective and orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), demonstrating IC50 values of 2.2 nM against wild-type ALK and various mutant forms, including F1197M, G1269A, L1196M, and S1206Y. This compound exhibits significant inhibitory activity against clinically relevant ALK mutants such as C1156Y and L1196M, as well as selectivity towards other kinases, including LTK, MERTK, CLK1, DAPK1, and DAPK2. CJ-2360 is suitable for studies focused on ALK-related cancers and the development of targeted therapies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • ALK/EGFR-IN-3
    Cat. No.
    A34526

    ALK/EGFR-IN-3

    ALK/EGFR-IN-3 is a potent dual inhibitor targeting both ALK and EGFR. It demonstrates significant anti-proliferative effects on H1975, PC9, and Baf3-EML4-ALK cancer cell lines, with IC50 values of 0.1360, 0.0332, and 0.0339 μM, respectively. This compound is valuable for research in cancer biology, specifically for studying treatment resistance and therapeutic strategies in tumors characterized by ALK and EGFR alterations.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes

Items 76-100 of 150

Added to your cart

View Cart Checkout

    Loading...